Clinical trial
A Phase I Dose-escalation Study to Assess the Safety of AFM11 (CD19 x CD3 TandAb®) in Patients With Relapsed or Refractory Adult B-precursor Acute Lymphoblastic Leukemia
NCT02848911 is registered in ClinicalTrials.gov with Affimed GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Dose-escalation Study to Assess the Safety of AFM11 (CD19 x CD3 TandAb®) in Patients With Relapsed or Refractory Adult B-precursor Acute Lymphoblastic Leukemia
- Lead sponsor
- Affimed GmbH
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 31, 2016
- Completion date
- April 30, 2019
- Enrollment
- 17 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.